Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 13/20 | 0.56 |
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
| ▸ | CAPN9 | O14815 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | CTSG | P08311 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSH | P09668 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982381 | 0.76 | CAPN1 (0.89) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL4777829 | 0.76 | CAPN1 (0.79) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL14067686 | 0.76 | CAPN1 (0.79) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL25896985 | 0.74 | CAPN1 (0.76) | CAPN1CTSBCAPN9MAPK1CTSL | |
| SCHEMBL8219586 | 0.72 | CAPN1 (0.81) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL3281530 | 0.72 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL1121089 | 0.72 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL10933522 | 0.72 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL10750447 | 0.72 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL | |
| E-64C SCHEMBL14067670 | 0.72 | CAPN1 (1.00) | CAPN1CTSBCAPN9MAPK1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1931656-A1 | NOVEL DRUGS FOR DEMENTIA | Ternansky, Robert (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007038772-A1 | NOVEL DRUGS FOR DEMENTIA | AMERICAN LIFE SCIENCE PHARMACEUTICALS (US) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227806-A1 | Novel Drugs for Dementia | CTSS, PRSS1, CBS | CAPN1 273/4885CTSB 49/4885CAPN9 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.